Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of blarcamesine in mild to moderate Alzheimer's disease
NCT02756858Phase 2Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Mar 2016
- Primary completion
- Nov 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blarcamesine in Alzheimer's disease (AD), sponsored by Anavex Life Sciences Corp. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 up to 208 weeks. Started Mar 2016; status: completed.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02756858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756858.